Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR4 | Q13639 | 4/20 | 0.56 |
| ▸ | CCR2 | P41597 | 6/20 | 0.54 |
| ▸ | CACNA1I | Q9P0X4 | 3/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.53 |
| ▸ | DRD2 | P14416 | 3/20 | 0.49 |
| ▸ | DRD4 | P21917 | 3/20 | 0.49 |
| ▸ | DRD3 | P35462 | 2/20 | 0.49 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6329791 | 0.92 | KCNH2 (0.61) | HTR4CCR2CACNA1IKCNH2DRD2 | |
| SCHEMBL6336876 | 0.92 | HTR4 (0.54) | HTR4CCR2CACNA1IKCNH2DRD2 | |
| SCHEMBL6329186 | 0.92 | HTR4 (0.66) | HTR4CCR2CACNA1IKCNH2DRD2 | |
| SCHEMBL6329269 | 0.92 | DRD2 (0.58) | HTR4DRD2DRD4DRD3ACHE | |
| SCHEMBL6331374 | 0.92 | HTR4 (0.56) | HTR4CCR2CACNA1IKCNH2DRD2 | |
| SCHEMBL6329054 | 0.91 | TP53 (0.57) | HTR4CACNA1IKCNH2DRD2DRD4 | |
| SCHEMBL6335672 | 0.90 | HTR4 (0.52) | HTR4CCR2CACNA1IKCNH2DRD2 | |
| SCHEMBL6335680 | 0.90 | HTR4 (0.54) | HTR4CCR2CACNA1IKCNH2DRD2 | |
| SCHEMBL6336300 | 0.90 | CCR2 (0.59) | HTR4CCR2CACNA1IKCNH2DRD2 | |
| SCHEMBL6328760 | 0.89 | DRD2 (0.53) | HTR4CACNA1IKCNH2DRD2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6979690-B2 | Oxo or oxy-pyridine compounds as 5-HT4 receptor modulators | PFIZER INC. (US) | 2005-12-27 | — | — | US | disclosed |
| US-20030207875-A1 | Oxo or oxy-pyridine compounds as 5-HT4 receptor modulators | PFIZER INC | 2003-11-06 | — | — | US | disclosed |
| EP-1325921-A2 | Oxo or oxy-pyridine compounds as 5-HT4 receptor modulators | Pfizer Inc. (US) | 2003-07-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207875-A1 | Oxo or oxy-pyridine compounds as 5-HT4 receptor modulators | HRH4, HRH2, HTR4 | HTR4 3/4885CCR2 427/4885CACNA1I 1644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.